FIELD: medicine.
SUBSTANCE: invention relates to a indasole derivative that has the following formula 
, or its pharmaceutically acceptable salt, as well as a pharmaceutical composition containing it. The invention relates to methods for treatment of disorders characterized by the activation of Wnt-signalling pathways (e.g., cancer, abnormal cell proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), including introduction of a therapeutically effective amount of this compound or pharmaceutically acceptable salt thereof. This compound can also be used in modulation of cellular events, mediated by Wnt-signalling, as well as for treatment of genetic diseases and neurological conditions/disorders/diseases due to mutations or disregulation of the Wnt pathway and/or one or more components of Wnt-signalling.
EFFECT: inhibits the Wnt signalling pathway and can be used to treat various diseases and pathologies.
28 cl, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDAZOLIE WNT SIGNAL PATHWAY INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | 2017 |
|
RU2682245C1 |
| INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/β-CATENIN SIGNAL INHIBITORS | 2012 |
|
RU2627693C2 |
| 1H-PYRAZOLO[3,4-B]PYRIDINES AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2689141C2 |
| METHODS FOR USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF WNT/B-CATENIN SIGNAL PATH | 2017 |
|
RU2770613C2 |
| NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
| PYRAZOLE DERIVATIVE SUITABLE AS PI3K INHIBITOR | 2016 |
|
RU2710549C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
